Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency-related reintervention rate of 1.3 per patient year.
At AAN 2026, Cabaletta Bio announced positive results from the Phase I/II open-label, RESET-MG study of rese-cel in patients with gMG.
Roche has reported new findings from the Phase III METEOROID trial of Enspryng in adults and adolescents with MOGAD.
At AAN 2026, Argenx announced positive results from the Phase III, double-blind, placebo-controlled, ADAPT SERON study of Vyvgart.
Currently in Phase I development, TherVacB is a therapeutic vaccine candidate designed as an immune therapy for chronic hepatitis B patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results